ponesimod (Ponvory) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Ponesimod, sold under the brand name Ponvory, is a medication for the treatment of multiple sclerosis. It is a sphingosine-1-phosphate receptor modulator.   Wikipedia

Chemistry

  • SMILES: CCC/N=C1\S/C(=C\c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C
  • InChIKey: LPAUOXUZGSBGDU-STDDISTJSA-N
  • Mol. Mass: 460.98
  • ALogP: 4.27
  • ChEMBL Molecule:
    ponesimod  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Alternative names

5-(3-chloro-4-(2,3-dihydroxy-propoxy)benzylidene)-2-propylimino-3-o-tolyl-thiazolidin-4-one | act128800 | act 128800 | act-128800 | ponesimod

Organizations (4)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (1)


 

Multiple Sclerosis (approved 2021)

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Graft vs Host Disease (Phase 2)

Healthy Volunteers (Phase 1)

Multiple Sclerosis (Phase 3)

Pharmacokinetics (Phase 1)

Pharmacological and Toxicological Phenomena (Phase 1)

Psoriasis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 15
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue